Tumor-associated neutrophils are known to express checkpoint inhibitory molecules such as PD-L1 and CD86 that can directly inhibit T cells (53, 54), and a dysfunctional neutrophil profile has been detected in patients with multiple myeloma (55–57). The gene discussed is CD86; the disease is neoplasm.